Literature DB >> 10651627

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.

S G Hymowitz1, M P O'Connell, M H Ultsch, A Hurst, K Totpal, A Ashkenazi, A M de Vos, R F Kelley.   

Abstract

Apoptosis-inducing ligand 2 (Apo2L, also called TRAIL), a member of the tumor necrosis factor (TNF) family, induces apoptosis in a variety of human tumor cell lines but not in normal cells [Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. (1995) Immunity 3, 673-682; Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. (1996) J. Biol. Chem. 271, 12687-12690]. Here we describe the structure of Apo2L at 1.3 A resolution and use alanine-scanning mutagenesis to map the receptor contact regions. The structure reveals a homotrimeric protein that resembles TNF with receptor-binding epitopes at the interface between monomers. A zinc ion is buried at the trimer interface, coordinated by the single cysteine residue of each monomer. The zinc ion is required for maintaining the native structure and stability and, hence, the biological activity of Apo2L. This is the first example of metal-dependent oligomerization and function of a cytokine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651627     DOI: 10.1021/bi992242l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  57 in total

1.  Leachables from saline-containing IV bags can alter therapeutic protein properties.

Authors:  Judy Y Chang; Nina J Xiao; Min Zhu; Jennifer Zhang; Ed Hoff; Stephen J Russell; Viswanatham Katta; Steven J Shire
Journal:  Pharm Res       Date:  2010-06-30       Impact factor: 4.200

2.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

Review 3.  Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors.

Authors:  Christopher C Valley; Andrew K Lewis; Jonathan N Sachs
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-01-12       Impact factor: 3.747

4.  A simplified method for the efficient purification and refolding of recombinant human TRAIL.

Authors:  Zhenjiang Zhang; Su Bin Hahn; Thong M Cao; Michael R King
Journal:  Biotechnol Prog       Date:  2020-05-11

5.  RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.

Authors:  Tadashi Mori; Akihiro Oguro; Takashi Ohtsu; Yoshikazu Nakamura
Journal:  Nucleic Acids Res       Date:  2004-11-23       Impact factor: 16.971

6.  Improved isolation of anti-rhTNF-alpha scFvs from phage display library by bioinformatics.

Authors:  Wei Chen; Juan Zhang; Tao Zhang; Haixin Li; Wenyi Wang; Zhinan Xia; Min Wang
Journal:  Mol Biotechnol       Date:  2009-05-02       Impact factor: 2.695

7.  Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

Authors:  Almer M van der Sloot; Vicente Tur; Eva Szegezdi; Margaret M Mullally; Robbert H Cool; Afshin Samali; Luis Serrano; Wim J Quax
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

8.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

9.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

Authors:  Moonsup Jeong; Yong-Sam Kwon; Soon-Hye Park; Chae-Young Kim; Sin-Soo Jeun; Kang-Won Song; Yong Ko; Paul D Robbins; Timothy R Billiar; Byong-Moon Kim; Dai-Wu Seol
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.